<a href=Pfizer” height=”225″ src=”https://www.drugdevelopment-technology.com/wp-content/uploads/static-progressive/nri/pharma/news/800px-Pfizer_world_HQ_jeh.JPG” style=”padding: 10px” width=”300″ />

Pfizer has reported positive results from a double-blind, Phase 3 study of pregabalin controlled-release (CR) formulation as treatment for fibromyalgia patients.

According to the study data, pregabalin CR demonstrated a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

Pfizer global primary care business unit, medicines development group, head and senior vice president Steven Romano said the results from controlled release studies will help in better understanding of the potential of a once-a-day pregabalin treatment regimen.

"Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes," Romano added.

The placebo-controlled, multi-centre study composed of 4 phases was designed to evaluate the efficacy and safety profile of pregabalin CR as treatment for fibromyalgia patients.

"Pregabalin CR demonstrated a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response."

Primary end-point, time to LTR during DB, occurred in 34 of 63 (54.0%) patients in the pregabalin group as compared with 41 of 58 (70.7%) subjects in the placebo group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study reported a 58-day median time from randomisation to LTR in the pregabalin group and 22 days in the placebo group, as well as observed statistically significant difference between the treatments.

Pregabalin CR, which was well tolerated in the study, demonstrated a safety profile similar to the identified profile for pregabalin (immediate release) in fibromyalgia patients.

Dizziness, somnolence, peripheral edema, insomnia, headache, fatigue, nausea, weight increased, vision blurred, dry mouth and disturbance in attention were adverse events reported in 5% or more of study’s subjects.

Image: Pfizer pregabalin CR formulation showed positive effect compared to placebo in Phase 3 fibromyalgia study. Photo: courtesy of Jim.henderson.